不可切除肝内胆管癌:多参数MR成像预测患者生存
本研究纳入94例不可切除肝内胆管癌患者,在经动脉化疗栓塞(TACE)前后行MR成像并随访至死亡或研究结束。采用半自动软件测量解剖学参数(RECIST直径、肿瘤体积)和功能学参数(存活肿瘤体积、存活肿瘤负荷、ADC),评估其与总生存的关系。结果显示ADC升高、存活肿瘤体积和存活肿瘤负荷下降与更高生存相关,多变量分析中ADC、三维mRECIST和存活肿瘤负荷无应答者的风险比分别为2.9、4.1和4.0。
要点
- TACE后ADC升高20.7%、存活肿瘤体积下降29.3%、存活肿瘤负荷下降29.1%(P均<.001)。
- ADC升高25%、存活肿瘤体积下降66%、存活肿瘤负荷下降50%的应答者总生存更高(log-rank P<.05)。
- 多变量分析中ADC、三维mRECIST、存活肿瘤负荷无应答者的风险比分别为2.9、4.1、4.0。
核心结论
- MR成像上ADC、存活肿瘤体积和存活肿瘤负荷的变化可为接受TACE的不可切除肝内胆管癌患者提供预后信息。
研究设计与样本
- 研究纳入94例不可切除肝内胆管癌患者,在TACE前后行MR成像并随访至死亡或研究结束,采用半自动软件分析病灶的解剖学和功能学容积参数,以总生存为主要终点,采用Cox回归和Kaplan-Meier生存分析。
关键影像表现/征象
- TACE后肿瘤体积无变化(P=.07),而RECIST直径显示小幅变化(-2.6%;P=.02)。
- TACE后ADC升高20.7%,存活肿瘤体积下降29.3%,存活肿瘤负荷下降29.1%(P均<.001)。
诊断标准与关键数值
- 以ADC升高25%、存活肿瘤体积下降66%、存活肿瘤负荷下降50%为应答阈值时,应答者总生存更高(log-rank检验,P<.05)。
- 多变量分析中,以ADC、三维mRECIST、存活肿瘤负荷判定的无应答者风险比分别为2.9(P=.004)、4.1(P=.009)、4.0(P=.002)。
- 以ADC、三维mRECIST和存活肿瘤负荷三项参数均显示应答者、其中一项或两项显示应答者、以及无应答者之间总生存存在差异(P<.001)。
临床应用与阅片要点
- 阅片时可基于TACE前后MR成像测量ADC、存活肿瘤体积和存活肿瘤负荷的变化,用于评估治疗应答和预后分层。
- RECIST直径变化幅度较小(-2.6%),而肿瘤体积无显著变化(P=.07),提示解剖学径线指标可能不如功能学容积参数敏感。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To determine the performance of magnetic resonance (MR) imaging-based tumor metrics for evaluation of response to transarterial chemoembolization (TACE) in patients with unresectable intrahepatic cholangiocarcinoma (ICCA). Materials and Methods Ninety-four patients with unresectable ICCA underwent baseline and follow-up MR imaging after TACE and were followed up until death or end of study duration. Lesions were analyzed for anatomic (Response Evaluation Criteria in Solid Tumors [RECIST] and tumor volume) and functional (viable tumor volume, viable tumor burden, and apparent diffusion coefficient [ADC]) volumetric MR parameters by using semiautomatic software. Response was assessed by using changes in viable tumor volume by using modified RECIST (mRECIST)-derived thresholds (three-dimensional mRECIST), viable tumor burden, and ADC. Overall survival was the primary endpoint. Cox-regression and Kaplan-Meier survival analysis were used. Results Tumor volume did not change after TACE (P = .07) whereas RECIST diameter showed a small change (-2.6%; P = .02). There was an increase in ADC (20.7%) and a decrease in viable tumor volume (-29.3%) and viable tumor burden (-29.1%; P < .001 for all). Higher overall survival was noted among responders by using thresholds of 25% increase in ADC, 66% decrease in viable tumor volume, and 50% decrease in viable tumor burden (log-rank test, P < .05). Hazard ratio for nonresponders by using ADC, three-dimensional mRECIST, and viable tumor burden at multivariable analysis was 2.9 (P = .004), 4.1 (P = .009), and 4.0 (P = .002), respectively. Survival differences were noted for patients who showed response by using all three parameters (ADC, three-dimensional mRECIST, and viable tumor burden) versus those who showed response by using either one or two of these parameters versus those who showed no response (P < .001). Conclusion Changes in volumetric ADC, viable tumor volume, and viable tumor burden at MR imaging provide prognostic information among patients with unresectable ICCA who undergo TACE. © RSNA, 2018 Online supplemental material is available for this article.
引用
- Pandey A, Pandey P, Aliyari Ghasabeh M, et al. Unresectable Intrahepatic Cholangiocarcinoma: Multiparametric MR Imaging to Predict Patient Survival. Radiology. 2018. PMID: 29584595. doi:10.1148/radiol.2018171593
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。